Latest & greatest articles for donepezil

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on donepezil or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on donepezil and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for donepezil

41. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technology Assessment 2006; 10(1): 1-176 Authors' objectives The objective of this review was to provide an update review of the best quality evidence for the clinical effectiveness and cost

2006 Health Technology Assessment (HTA) Database.

42. Donepezil improves cognitive function and reduces decline in activities of daily living in people with severe Alzheimer’s disease

Donepezil improves cognitive function and reduces decline in activities of daily living in people with severe Alzheimer’s disease Donepezil improves cognitive function and reduces decline in activities of daily living in people with severe Alzheimer’s disease | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Donepezil improves cognitive function and reduces decline in activities of daily living in people with severe Alzheimer’s disease

2006 Evidence-Based Mental Health

43. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 111. 2006 Authors' objectives This guidance constitutes a review of 'NICE technology appraisal guidance 19' on the use of donepezil, galantamine and rivastigmine for the treatment of mild to moderately

2006 Health Technology Assessment (HTA) Database.

44. Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer’s disease

Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer’s disease Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer’s disease | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer’s disease Article Text

Full Text available with Trip Pro

2005 Evidence-Based Mental Health

45. Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease

Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease Article Text Therapeutics Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease Free James Warner

Full Text available with Trip Pro

2005 Evidence-Based Mental Health

46. Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease

Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease Article Text Therapeutics Memantine plus donepezil improves physical and mental health in people

Full Text available with Trip Pro

2005 Evidence-Based Mental Health

47. Donepezil slows decline in daily life activities in people with moderate to severe Alzheimer’s disease and alleviates caregiver burden

Donepezil slows decline in daily life activities in people with moderate to severe Alzheimer’s disease and alleviates caregiver burden Donepezil slows decline in daily life activities in people with moderate to severe Alzheimer’s disease and alleviates caregiver burden | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Donepezil slows decline in daily life activities in people with moderate to severe Alzheimer’s disease and alleviates

Full Text available with Trip Pro

2005 Evidence-Based Mental Health

48. Vitamin E and donepezil for the treatment of mild cognitive impairment. (PubMed)

Vitamin E and donepezil for the treatment of mild cognitive impairment. Mild cognitive impairment is a transitional state between the cognitive changes of normal aging and early Alzheimer's disease.In a double-blind study, we evaluated subjects with the amnestic subtype of mild cognitive impairment. Subjects were randomly assigned to receive 2000 IU of vitamin E daily, 10 mg of donepezil daily, or placebo for three years. The primary outcome was clinically possible or probable Alzheimer's (...) ) or the donepezil group (hazard ratio, 0.80; 95 percent confidence interval, 0.57 to 1.13; P=0.42) during the three years of treatment. Prespecified analyses of the treatment effects at 6-month intervals showed that as compared with the placebo group, the donepezil group had a reduced likelihood of progression to Alzheimer's disease during the first 12 months of the study (P=0.04), a finding supported by the secondary outcome measures. Among carriers of one or more apolipoprotein E epsilon4 alleles, the benefit

2005 NEJM

49. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis

A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

50. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. (PubMed)

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Cholinesterase inhibitors produce small improvements in cognitive and global assessments in Alzheimer's disease. We aimed to determine whether donepezil produces worthwhile improvements in disability, dependency, behavioural and psychological symptoms, carers' psychological wellbeing, or delay in institutionalisation. If so, which patients benefit, from what dose, and for how long?565 (...) community-resident patients with mild to moderate Alzheimer's disease entered a 12-week run-in period in which they were randomly allocated donepezil (5 mg/day) or placebo. 486 who completed this period were rerandomised to either donepezil (5 or 10 mg/day) or placebo, with double-blind treatment continuing as long as judged appropriate. Primary endpoints were entry to institutional care and progression of disability, defined by loss of either two of four basic, or six of 11 instrumental, activities

2004 Lancet

51. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. (PubMed)

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist. Controlled trials have demonstrated the safety and efficacy of memantine monotherapy for patients with moderate to severe Alzheimer disease (AD) but no controlled trials of memantine in patients receiving a cholinesterase inhibitor have been performed.To compare (...) the efficacy and safety of memantine vs placebo in patients with moderate to severe AD already receiving stable treatment with donepezil.A randomized, double-blind, placebo-controlled clinical trial of 404 patients with moderate to severe AD and Mini-Mental State Examination scores of 5 to 14, who received stable doses of donepezil, conducted at 37 US sites between June 11, 2001, and June 3, 2002. A total of 322 patients (80%) completed the trial.Participants were randomized to receive memantine (starting

Full Text available with Trip Pro

2004 JAMA

52. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

53. Donepezil for dementia due to Alzheimer's disease. (PubMed)

Donepezil for dementia due to Alzheimer's disease. Alzheimer's disease is the most common cause of dementia in older people. One of the aims of therapy is to inhibit the breakdown of a chemical neurotransmitter, acetylcholine, by blocking the relevant enzyme. This can be done by a group of chemicals known as cholinesterase inhibitors. However, some (like tacrine) are associated with adverse effects such as hepatotoxicity, but donepezil (E2020, Aricept) is safer.The objective of this review (...) is to assess whether donepezil improves the well-being of patients with dementia due to Alzheimer's disease.The Cochrane Dementia and Cognitive Improvement Group's Specialized Register was searched using the terms 'donepezil', 'E2020' and 'Aricept' on 9 October 2002. This Register contains up-to-date records of all major health care databases and many ongoing trial databases. Members of the Donepezil Study Group and Eisai Inc were contacted.All unconfounded, double-blind, randomized controlled trials

2003 Cochrane

54. The value of the managed entry of new drugs: a case study of donepezil

The value of the managed entry of new drugs: a case study of donepezil The value of the managed entry of new drugs: a case study of donepezil The value of the managed entry of new drugs: a case study of donepezil Payne K, Davies L M, Noyce P R, Weiss M C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Three models to manage the entry of new drugs (in the case, donepezil) into practice were examined. In model 1, the Health Authority managed the entry of donepezil by using existing services with consultant assessment and general practitioners (GPs) taking up prescribing after 5 weeks. In model 2, the Health Authority managed the entry of donepezil by using existing services with consultant-only prescribing. In model 3, the Health

2003 NHS Economic Evaluation Database.

55. Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia

Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia Fajemisin B Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Fajemisin B. Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia. London: Bazian Ltd (Editors), Wessex Institute for Health Research and Development, University of Southampton 2002: 9 Authors' objectives This study aims to assess the effects of acetylcholinesterase inhibitors (donepezil, rivastigmine, tacrine, galantamine) on functional outcomes in people with non-Alzheimer's dementia. Authors' conclusions We found

2002 Health Technology Assessment (HTA) Database.

56. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost effectiveness

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost effectiveness Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost effectiveness Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost effectiveness Wolfson C, Oremus M, Shukla (...) V, Momoli F, Demers L, Perrault A, Moride Y Authors' objectives To assess the efficacy and safety of donepezil and rivastigmine in the treatment of Alzheimer's disease (AD). Searching MEDLINE, HealthSTAR and PsycINFO were searched from January 1984 to May 2000; the key terms were stated. Unpublished studies and abstracts were excluded. The reference lists in identified studies were handsearched. The search was updated by searching the same databases from May 2000 to October 2001. Study selection

2002 DARE.

57. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan

Economic evaluation of donepezil treatment for Alzheimer's disease in Japan Economic evaluation of donepezil treatment for Alzheimer's disease in Japan Economic evaluation of donepezil treatment for Alzheimer's disease in Japan Ikeda S, Yamada Y, Ikegami N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology The use of donepezil (Aricept) for the treatment of mild and moderate Alzheimer's disease (AD). Patients were assumed to receive donepezil at 3 mg/day for 1 week after the start of treatment and at 5 mg/day thereafter. The comparator was standard therapy. Type of intervention Secondary prevention and palliative care. Economic study type Cost-utility analysis. Study population The study population comprised patients

2002 NHS Economic Evaluation Database.

58. Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review

Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N Authors' objectives To provide a rapid (...) and systematic review of the clinical effectiveness and cost-effectiveness of donepezil, rivastigmine and galantamine in the symptomatic treatment of people suffering from Alzheimer's disease (AD). Searching The following databases were searched from their inception to March to July, 2000: MEDLINE, EMBASE, the Cochrane Library, DARE, NHS EED, the National Researh Register, the Science Citation Index, BIOSIS Previews, EconLit, the MRC Clinical Trials Directory, an Early Warning System database, Current

2001 DARE.

59. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease

Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation National Institute for Clinical Excellence. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 19. 2001 Authors' objectives To provide guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. Authors' conclusions Guidance 1.1 The three drugs donepezil, rivastigmine

2001 Health Technology Assessment (HTA) Database.

60. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review

Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review. Health Technology Assessment 2001; 5(1): 1-137 Authors' objectives To provide a rapid and systematic review of the clinical

2001 Health Technology Assessment (HTA) Database.